Education
About Us
Working with TipRanks
Follow Us
AptarGroup (ATR)
NYSE:ATR
ATR Stock Chart & Stats
$140.01
-$0.05(-0.03%)
At close: 4:00 PM EST
$140.01
-$0.05(-0.03%)
Day’s Range― - ―
52-Week Range$103.23 - $164.28
Previous CloseN/A
Volume34.64K
Average Volume (3M)495.53K
Market Cap
$9.01B
Enterprise Value$9.96B
Total Cash (Recent Filing)$409.53M
Total Debt (Recent Filing)$1.14B
Price to Earnings (P/E)23.8
Beta0.54
Next Earnings
Apr 30, 2026EPS Estimate
1.15Next Dividend Ex-DateN/A
Dividend Yield1.5%
Share Statistics
EPS (TTM)1.25
Shares Outstanding64,379,740
10 Day Avg. Volume752,012
30 Day Avg. Volume495,530
Financial Highlights & Ratios
PEG Ratio3.60
Price to Book (P/B)3.01
Price to Sales (P/S)2.12
P/FCF Ratio26.76
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue2.64
Enterprise Value/Gross Profit8.91
Enterprise Value/Ebitda11.98
Forecast
1Y Price Target
$145.33Price Target Upside3.80% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyAcquisition of Sommaplast expands the company's Latin American footprint and presents synergy opportunities within the pharma business to augment future growth.
Beauty RecoveryReturn to growth in the beauty segment after a prolonged decline signals a turnaround that can bolster overall sales momentum.
Segment GrowthStrong revenue growth across the pharma, beauty and closures segments indicates broad-based demand that can support top-line expansion.
Bears Say
Operational RiskUnusual maintenance problems and a supplier fire disrupted operations and raised execution risk that could continue to weigh on results.
Product DemandDeclining demand for emergency medicines, including reduced Narcan interest, creates a meaningful revenue headwind that can pressure growth expectations.
ProfitabilityLoss of higher-margin product revenue alongside increased lower-margin tooling sales has weakened margins and could constrain earnings improvement.
AptarGroup News
ATR FAQ
What was AptarGroup’s price range in the past 12 months?
AptarGroup lowest stock price was $103.23 and its highest was $164.28 in the past 12 months.
What is AptarGroup’s market cap?
AptarGroup’s market cap is $9.01B.
When is AptarGroup’s upcoming earnings report date?
AptarGroup’s upcoming earnings report date is Apr 30, 2026 which is in 75 days.
How were AptarGroup’s earnings last quarter?
AptarGroup released its earnings results on Feb 05, 2026. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.229 by $0.021.
Is AptarGroup overvalued?
According to Wall Street analysts AptarGroup’s price is currently Undervalued.
Does AptarGroup pay dividends?
AptarGroup pays a Quarterly dividend of $0.48 which represents an annual dividend yield of 1.5%. See more information on AptarGroup dividends here
What is AptarGroup’s EPS estimate?
AptarGroup’s EPS estimate is 1.15.
How many shares outstanding does AptarGroup have?
AptarGroup has 64,379,740 shares outstanding.
What happened to AptarGroup’s price movement after its last earnings report?
AptarGroup reported an EPS of $1.25 in its last earnings report, beating expectations of $1.229. Following the earnings report the stock price went up 8.332%.
Which hedge fund is a major shareholder of AptarGroup?
Currently, no hedge funds are holding shares in ATR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AptarGroup Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$145.33 (3.80% Upside)
$145.33 (3.80% Upside)
Blogger Sentiment
Bullish
ATR Sentiment 71%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 18.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 11.1%
Last 30 Days ▼ 11.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.98%
12-Months-Change
Fundamentals
Return on Equity
15.28%
Trailing 12-Months
Asset Growth
18.51%
Trailing 12-Months
Company Description
AptarGroup
AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. It sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. The company has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
ATR Company Deck
ATR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of clear operational and commercial strengths—notably strong Q4 revenue growth, sustained Pharma pipeline momentum (including FDA approval of CARDAMYST), meaningful tooling and commercial wins in Beauty and Closures, solid capital returns and a healthy balance sheet—while also disclosing significant near-term margin pressures driven by emergency medicine destocking (~$65 million headwind), operational disruptions in Beauty and Closures, higher interest and tax expenses, and a sizable Q4 EPS decline. Management emphasized that many negative items are transitory, expects sequential margin improvement through 2026 and reaffirmed productivity programs and buyback flexibility. Overall, positive revenue and pipeline momentum are meaningfully offset by near-term margin and cost challenges, leaving a balanced outlook.View all ATR earnings summariesATR Stock 12 Month Forecast
Average Price Target
$145.33
▲(3.80% Upside)
Technical Analysis
Baxter International
―
Cooper Co
―
Repligen
―
West Pharmaceutical Services
―
Stevanato Group
―
Ownership Overview
0.64% Insiders
31.20% Mutual Funds
0.53% Other Institutional Investors
43.48% Public Companies and
Individual Investors